You’re raising fair questions, but the logic still points in one direction.
1. On the valuation question No, I haven’t seen Advent’s private financials — and neither have you. But we don’t need the private books to understand the value bracket. Advent is:
• a licensed, MHRA-inspected commercial ATMP manufacturing facility
• with built cleanrooms, validated equipment, and trained GMP staff
• already producing DCVax-L under both IMP and commercial MIA
• located in one of the most expensive biotech hubs in Europe
A facility with those characteristics simply does not trade for $20M or $30M. Every comparable ATMP facility acquisition in the last 5–7 years lands in the $150–300M range. So using a $200–250M working estimate is not fantasy — it’s benchmarking.
If you believe Advent is worth dramatically less, you need to present a credible comp s
2. “If approval was coming, Advent would benefit anyway — so why donate?” This argument sounds logical on the surface, but it misses the capital-structure reality.
If LP kept Advent outside NWBO:
• she keeps 75% of the Advent equity
• she captures almost all of the upside privately
• and she shields it from NWBO’s dilution, volatility, and OTC risk
That is the rational path if there is ANY meaningful risk of failure.
Instead, she chose the exact opposite: She folded Advent into the most diluted, highest-risk entity — right before approval decisions.
Why does that matter?
Because this is not how an owner behaves if they fear rejection. You do not merge a private, appreciating GMP asset into a public microcap unless you believe:
• the approval path is on track,
• commercialization is imminent, and
• a unified corporate structure is required for scale.
If LP thought approval was questionable, the smart move was to keep Advent separate and monetize it independently. She didn’t.
3. “Why dilute herself from 75% to under 10%?” Because ownership percentage is irrelevant if the total pie becomes exponentially larger.
75% of a private company with capped market visibility vs. 10% of a commercial-stage oncology company with global manufacturing capacity
These are not equivalent.
People fixate on dilution percentage, but sophisticated owners focus on:
• total enterprise value,
• cost of capital,
• commercial scalability,
• and regulatory alignment.
LP made a decision that only makes sense if Advent inside NWBO is projected to be worth far more than Advent outside NWBO.
4. The core issue remains unchanged If LP had any internal belief that DCVax-L faced a real risk of regulatory rejection, the optimal move was:
• keep Advent private,
• maintain control,
• isolate the asset from NWBO’s binary risk.
Instead, she did the riskiest possible thing — unless she is extremely confident in the outcome.
That is why this is the strongest insider signal in the entire NWBO narrative.
Market Data 
Markets 
AI
